Roflumilast for Chronic Plaque Psoriasis
- 20 September 2022
- journal article
- editorial
- Published by American Medical Association (AMA) in JAMA
- Vol. 328 (11), 1049-1050
- https://doi.org/10.1001/jama.2022.14663
Abstract
Plaque psoriasis is a multisystem inflammatory disease that affects children and adults. Skin lesions are the most prominent manifestation, appearing as localized or widespread red plaques with silvery scale. Psoriasis may be associated with arthritis, obesity, metabolic syndrome, psychiatric disease, impaired quality of life, and increased risk of cardiovascular disease.1 The etiology and precise pathogenesis of psoriasis remain unclear. Treatment selection depends on body surface area affected, lesion characteristics (thickness, location), symptoms such as itch and pain, and comorbidities. Topical medications are prescribed in almost all cases, alone or in combination with other therapies.2This publication has 14 references indexed in Scilit:
- Trial of Roflumilast Cream for Chronic Plaque PsoriasisThe New England Journal of Medicine, 2020
- Vehicles for atopic dermatitis therapies: more than just a placeboJournal of Dermatological Treatment, 2020
- Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologicsJournal of the American Academy of Dermatology, 2019
- Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with awareness and attention to comorbiditiesJournal of the American Academy of Dermatology, 2019
- Adherence in dermatologyJournal of Dermatological Treatment, 2016
- Psychometric properties of the Itch Numeric Rating Scale in patients with moderate‐to‐severe plaque psoriasisBritish Journal of Dermatology, 2016
- Psoriasis and ObesityDermatology, 2016
- The 5-point Investigator’s Global Assessment (IGA) Scale: A modified tool for evaluating plaque psoriasis severity in clinical trialsJournal of Dermatological Treatment, 2013
- The Psoriasis Symptom Diary: development and content validity of a novel patient‐reported outcome instrumentInternational Journal of Dermatology, 2013
- A 50% reduction in the Psoriasis Area and Severity Index (PASI 50) is a clinically significant endpoint in the assessment of psoriasisJournal of the American Academy of Dermatology, 2004